EGFRvIII-targeted IgT cells

Antigen-specific IgT cells are an investigational adoptive cell therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of glioblastoma multiforme (GBM) and leptomeningeal disease. The therapy consists of autologous T lymphocytes that have undergone "immunogene modification" (IgT) to express chimeric antigen receptors (CARs) targeting the epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific mutation frequently found in GBM but absent in healthy tissues. The CAR construct typically incorporates a 4-1BB co-stimulatory domain to promote T-cell survival and persistence, and may include an inducible caspase 9 (iCasp9) suicide gene as a safety switch to mitigate potential toxicities such as cytokine release syndrome or neurotoxicity. The therapy is designed for delivery via multiple routes, including intravenous, intrathecal, and intracranial injections, to optimize the targeting of aggressive brain tumor cells that are often resistant to standard-of-care treatments.

Other names

EGFRvIII-specific CAR-T cellsEGFRvIII-CAR-TAntigen-specific IgT cells